MX374835B - Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales. - Google Patents

Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.

Info

Publication number
MX374835B
MX374835B MX2014001721A MX2014001721A MX374835B MX 374835 B MX374835 B MX 374835B MX 2014001721 A MX2014001721 A MX 2014001721A MX 2014001721 A MX2014001721 A MX 2014001721A MX 374835 B MX374835 B MX 374835B
Authority
MX
Mexico
Prior art keywords
quinazolinone
analogues
treat
viral infections
prevent certain
Prior art date
Application number
MX2014001721A
Other languages
English (en)
Other versions
MX2014001721A (es
Inventor
Jiwen Zou
Marintha L Heil
Nicholas D P Cosford
Robert Ardecky
Original Assignee
Southern Res Inst
Sanford Burnham Med Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst, Sanford Burnham Med Res Inst filed Critical Southern Res Inst
Publication of MX2014001721A publication Critical patent/MX2014001721A/es
Publication of MX374835B publication Critical patent/MX374835B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un proceso para tratar o prevenir una infección viral en un sujeto, en donde la infección viral es de un flavivirus seleccionado del grupo que consiste del virus de Hepatitis C (genotipos 1-7) y Virus de Encefalitis Japonesa. El proceso incluye administrar al sujeto una cantidad terapéuticamente efectiva de al menos un compuesto representado por la fórmula: (Fórmula (I)) (ver Fórmula).
MX2014001721A 2011-08-12 2012-08-10 Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales. MX374835B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161522859P 2011-08-12 2011-08-12
PCT/US2012/050347 WO2013025508A1 (en) 2011-08-12 2012-08-10 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections

Publications (2)

Publication Number Publication Date
MX2014001721A MX2014001721A (es) 2017-01-11
MX374835B true MX374835B (es) 2025-03-06

Family

ID=47715390

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001721A MX374835B (es) 2011-08-12 2012-08-10 Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.

Country Status (11)

Country Link
US (2) US9598402B2 (es)
EP (1) EP2744787B1 (es)
JP (1) JP6041877B2 (es)
CN (1) CN103889963B (es)
AU (1) AU2012295290B2 (es)
BR (1) BR112014003003A2 (es)
CA (1) CA2844091C (es)
ES (1) ES2616342T3 (es)
MX (1) MX374835B (es)
WO (1) WO2013025508A1 (es)
ZA (1) ZA201400940B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374835B (es) * 2011-08-12 2025-03-06 Southern Res Inst Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.
ES2544519B1 (es) 2015-05-22 2016-03-04 Consejo Superior De Investigaciones Científicas (Csic) Quinazolinas S-sustituidas y sus aplicaciones terapéuticas para el tratamiento de enfermedades mediadas por PDE7
CN107793369B (zh) * 2017-10-27 2019-12-10 沈阳药科大学 2-[2-(2-甲氧基苯氧基)乙胺基]-3-芳基-4-喹唑啉酮类化合物及其应用
CN107868060B (zh) * 2017-10-27 2021-04-09 沈阳药科大学 2-[3-(4-吗啉基)丙胺基]-3-芳基-4-喹啉酮类化合物及其应用
EP3930837A4 (en) * 2019-02-27 2022-10-05 Cerepeut, Inc. QUINAZOLINONE COMPOUNDS
CN115636795B (zh) * 2022-11-02 2024-04-05 贵州理工学院 一种含硫代苯酰胺结构的喹唑啉酮类衍生物及其组合物的制备方法及其防治猕猴桃溃疡病的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200100642T2 (tr) * 1998-08-25 2001-07-23 Yale University Helioksantin ve analogları ile hepatit B virüsü ve flavivirüsün engellenmesi ve tedavisi.
ES2456702T3 (es) * 2003-05-09 2014-04-23 Boehringer Ingelheim International Gmbh Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C
WO2005049613A1 (en) 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
US20070191400A1 (en) 2004-03-24 2007-08-16 Rimonyx Pharmaceuticals Ltd. Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
ES2369282T3 (es) * 2005-03-25 2011-11-29 Tibotec Pharmaceuticals Inhibidores heterobicíclicos de vhc.
US20090035306A1 (en) * 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
RU2552533C2 (ru) 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
WO2011032277A1 (en) * 2009-09-18 2011-03-24 Boehringer Ingelheim International Gmbh Quinazolinone derivatives as viral polymerase inhibitors
CN101792440B (zh) * 2010-03-18 2011-12-28 华东师范大学 喹唑啉酮衍生物及其制备和应用
MX374835B (es) * 2011-08-12 2025-03-06 Southern Res Inst Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.

Also Published As

Publication number Publication date
JP2015506904A (ja) 2015-03-05
US20170144978A1 (en) 2017-05-25
ES2616342T3 (es) 2017-06-12
MX2014001721A (es) 2017-01-11
US20140256753A1 (en) 2014-09-11
BR112014003003A2 (pt) 2017-02-21
US10611733B2 (en) 2020-04-07
NZ622331A (en) 2015-11-27
AU2012295290A1 (en) 2014-02-27
WO2013025508A1 (en) 2013-02-21
AU2012295290B2 (en) 2017-06-15
EP2744787A4 (en) 2015-01-21
CN103889963B (zh) 2016-01-20
CN103889963A (zh) 2014-06-25
CA2844091A1 (en) 2013-02-21
JP6041877B2 (ja) 2016-12-14
EP2744787A1 (en) 2014-06-25
CA2844091C (en) 2017-07-18
EP2744787B1 (en) 2016-11-02
US9598402B2 (en) 2017-03-21
ZA201400940B (en) 2017-01-25

Similar Documents

Publication Publication Date Title
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
ECSP19011209A (es) Compuestos terapéuticos
ECSP14013315A (es) Inhibidores de aplicación viral
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
EA201791776A1 (ru) Замещенные циклофаны для использования при лечении инфекции вгс
UY37997A (es) Agentes antivirales contra la hepatitis b
ECSP20029558A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)
UY33897A (es) Inhibidores del virus de la hepatitis c
CO6561783A2 (es) Inhibidores del virus flaviviridae
ECSP13012622A (es) Compuestos antivirales
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
ECSP12011610A (es) Inhibidores de la replicación de los virus de la gripe
MX346264B (es) Compuestos antivirales.
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
CO2021011295A2 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
MX374835B (es) Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales.
UY34066A (es) Inhibidores del virus de la hepatitis c
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112015026243A2 (pt) método de inibição viral

Legal Events

Date Code Title Description
FG Grant or registration